More on ACXP

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+69.8% Growth)
- Ratings (10.0 Score)

Upcoming Events

- Earnings (8/14/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Acurx Pharmaceuticals (NQ:ACXP)
Delayed: 1.43 +0.01 (0.70%)
Prev. Close $1.42  
Open$1.44 
52 Wk High$ 
52 Wk Low$ 
Day High$1.49 
Day Low$1.42 
P/E N/A  
EPS$ 
Volume40,759 

Friends, Peers and Foes (?): PETV, RDZN, LASE, SNYR, AERT (more...)

Jul 14, 2026 08:00 AM Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
Jul 8, 2026 08:00 AM Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
Jun 16, 2026 08:02 AM ACURX drug research presented at Leiden conference
Jun 16, 2026 08:00 AM Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Develo
May 19, 2026 12:26 PM Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat
May 12, 2026 03:05 PM Form 424B3 Acurx Pharmaceuticals,
May 12, 2026 03:04 PM Form 424B3 Acurx Pharmaceuticals,
May 12, 2026 08:44 AM Acurx Pharmaceuticals (ACXP) Misses Q1 EPS by 62c
May 12, 2026 07:01 AM Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
May 12, 2026 06:07 AM Form EFFECT Acurx Pharmaceuticals,
View All Articles

Entities mentioned with ACXP

View All Entities